August 25, 2010
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology

August 20, 2010
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010

Check latest
stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Corporate News Release

Bioniche to Present at BioContact Quebec 2007

04/10/07

BELLEVILLE, ON, Oct. 4 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, announced that Cameron Groome, Executive Vice-President, Corporate & Strategic Development will present today at BioContact Quebec 2007, an annual biopharmaceutical partnership symposium being held in Quebec City this week. Mr. Groome will present at 10:00 a.m. (Eastern) in Salle Frontenac.

More than 150 biopharmaceutical companies are attending BioContact Quebec, from Canada, the United States, Asia and Europe. Companies represent diagnostics, therapeutics and services, covering such disciplines as Cancer, Cardiology, Genomics/Proteomics, Immunology/Infectiology and more.

The forum provides an opportunity to update peers in the biopharmaceutical industry about recent accomplishments of Bioniche, including the agreement with the U.S. Food & Drug Administration on a Special Protocol Assessment (SPA) for the Company's second Phase III pivotal clinical trial in first-line bladder cancer patients; the progress being made in the first Phase III clinical trial in refractory bladder cancer patients; the first commercial sales of its E. coli O157:H7 vaccine for cattle; and the vaccine's recognition as the best new veterinary product for livestock globally.

Back

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Food Safety
Human Health